Isracann Receives Foreign Owners License and Updates Israeli Cannabis Operations
License paves way for market penetration and growth opportunities
April 21, 2021 09:00 ET | Source: Isracann Biosciences Inc. Isracann Biosciences Inc. Vancouver, British Columbia, CANADA
VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce it has been granted a Foreign Owners Cannabis License by the Israeli Minister of Health. This important event paves the way to conclude a number of outstanding key partnership and regulatory considerations in preparation for commercial operations.
Isracann Receives Foreign Owners License and Updates Israeli Cannabis Operations
News Provided By
Share This Article
License paves way for market penetration and growth opportunities
/EIN News/ VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce it has been granted a Foreign Owners Cannabis License by the Israeli Minister of Health. This important event paves the way to conclude a number of outstanding key partnership and regulatory considerations in preparation for commercial operations.
Isracann Signs Cannabis Importation LOI with Major Israeli Manufacturer Canadian Export Product Aim to Help Reduce Shortages in Medical Supply Chain
March 03, 2021 09:00 ET | Source: Isracann Biosciences Inc. Isracann Biosciences Inc.
VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE)
Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce it has entered a non-binding Letter of Intent (LOI) outlining an importation sales agreement with a major Israeli medical cannabis company.
The proposed relationship is with one of the leading cannabis product manufacturers in Israel, who for commercial reasons can not be identified at this time. Imported goods will consist of premium Canadian cannabis via Isracann’s agreement with Costa Canna Group’s c
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Isracann Completes Phase One Construction at Cannabis Facility in Israel
Isracann Biosciences Inc.February 16, 2021 GMT
VANCOUVER, British Columbia, Feb. 16, 2021 (GLOBE NEWSWIRE) Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is pleased to announce its flagship Hefer Valley-based Ein Hahoresh Farm is in full readiness to commence growing and production activities.
With the phase one 54,000 sq. ft. of greenhouse canopy fully constructed and extensive processing capability in-place, Isracann is moving rapidly towards the commencement of industrial-scale operations aimed at servicing both domestic and European export markets in 2021.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Isracann Announces Launch of Early Warrant Exercise Incentive Program and Repricing
Isracann Biosciences Inc.January 11, 2021 GMT
VANCOUVER, British Columbia, Jan. 11, 2021 (GLOBE NEWSWIRE) Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer announces it has implemented a warrant exercise incentive program designed to encourage exercise of up to 20,574,216 of its outstanding share purchase warrants expiring on September 30, 2021 (the “Warrants”). The Company will amend the exercise price of the Warrants from $1.02 per common share of the Company (each, a “Share”) to $0.30 per Share, subject to acceleration. If, for any ten consecutive trading days during the unexpired term of the Warrants the closing price of the Shares on the Canadi